Table 3. Baseline factors associated with progression of atheromatous vascular disease (AVD) in all patients.
| AVDa progression | Non AVD progression | p | |
|---|---|---|---|
| (n = 89) | (n = 85) | ||
| Males (%) | 50 (56.2) | 45 (52.9) | 0.78 |
| Age (years) | 57 [48;65] | 50 [39;62] | 0.004 |
| Smoker (former/current) (%) | 53 (59.6) | 44 (51.8) | 0.38 |
| Diabetes (%) | 20 (22.5) | 8 (9.41) | 0.033 |
| Hypertension (%) | 79 (88.8) | 75 (88.2) | 1 |
| Dyslipidemia (%) | 59 (66.3) | 54 (63.5) | 0.824 |
| Etiology of renal disease (%): | 0.165 | ||
| Diabetic nephropathy | 25 (10.5) | 27 (11.4) | |
| Vascular disease | 23 (9.7) | 29 (12.2) | |
| Others | 69 (77.5) | 69 (81.2) | |
| Dialysis time (months) | 10.2 [4.4;23.2] | 11.8 [6.47;22.5] | 0.27 |
| Body mass index (kg/m2) | 27 [23.6;30.7] | 26.1 [23.1;28.8] | 0.156 |
| Systolic Blood Pressure (mmHg) | 142 (24.3) | 141 (24.3) | 0.735 |
| Diastolic Blood Pressure (mm Hg) | 82 (13.5) | 83.9 (13.5) | 0.343 |
| Pulse Pressure (mmHg) | 60 [44;74] | 56 [45;66] | 0.326 |
| Serum glucose (mmol/L) | 5.18 [4.54;6.10] | 5.05 [4.49;5.66] | 0.157 |
| Urea (mmol/L) | 18.3 (5.25) | 18.3 (5.21) | 0.984 |
| Creatinine (μmol/L) | 610 [486.2;797.4] | 662.1 [557.8;839.8] | 0.089 |
| Total colesterol (mmol/L) | 4.14 [3.63;4.89] | 4.45 [3.57;5.33] | 0.258 |
| HDL-cholesterol (mmol/L) | 1.10 [0.93;1.39] | 1.16 [0.96;1.37] | 0.561 |
| LDL-cholesterol (mmol/L) | 2.30 [1.85;2.82] | 2.61 [1.81;2.98] | 0.264 |
| Triglycerides (mmol/L) | 1.51 [1.11;2.10] | 1.38 [1.07;1.92] | 0.528 |
| Serum uric acid (μmol/L) | 370.5 (72.6) | 350.4 (70.8) | 0.084 |
| hs C-Reactive Protein (nmol/L) | 37.7 [13.8;65.9] | 18.5 [8.4;54.2] | 0.04 |
| Albumin (mol/L) | 0.59 [0.0.53;0.63] | 0.59 [0.54;0.62] | 0.613 |
| Hemoglobin (mmol/L) | 1.83 (0.25) | 1.83 (0.21) | 0.962 |
| Corrected calcium (mmol/L) | 2.31 [2.19;2.4] | 2.26 [2.12;2.37] | 0.419 |
| Phosphate (mmol/L) | 1.52 [1.26;1.81] | 1.55 [1.36;1.84] | 0.292 |
| iPTH (pmolL) | 24.7 [15.9;38.1] | 23.3 [15.27;36.7] | 0.586 |
| 25-hydroxy-vitamin D (nmol/L) | 30.9 [22.8;42.9] | 36.4 [26.7;48.7] | 0.043 |
| 1-25-hydroxy-vitamin D (pmol/L) | 14.9 [10.0;24.5] | 13.6 [9.7;22.3] | 0.602 |
| Treatments | |||
| Antihypertensive (%): | 68 (76.4) | 64 (75.3) | 1 |
| ACEIb (%) | 18 (20.2) | 17 (20) | 1 |
| ARBsc (%) | 29 (32.6) | 33 (38.8) | 0.483 |
| Diuretics (%) | 27 (32.6) | 28 (32.9) | 0.837 |
| Statins (%) | 51 (57.3) | 47 (55.3) | 0.9 |
| Phosphate binders (%): | 68 (76.4) | 66 (77.6) | 0.98 |
| Binders without Cad (%) | 39 (43.8) | 47 (55.3) | 0.173 |
| Binders with Cad (%) | 42 (47.2) | 40 (47.1) | 1 |
| Cad intake (binders) (gr/day) | 1 [1;1.5] | 1.5 [1;2.5] | |
| Calcitriol/Paricalcitol (%) | 45 (50.6) | 33 (38.8) | 0.16 |
| Calcifedol /%) | 9 (10.1) | 4 (4.71) | 0.286 |
| Cholecalciferol (%) | 3 (3.37) | 3 (3.53) | 1 |
| Cinacalcet (%) | 19 (21.3) | 23 (27.1) | 0.482 |
| Antiplatelet drugs (%): | 27 (30.3) | 22 (25.9) | 0.628 |
| ESAe (%) | 66 (74.2) | 73 (85.9) | 0.082 |
| Renal transplantation centre (%) | 22 (24.7) | 25 (29.4) | 0.599 |
| Plaque at baseline (%) | 64 (71.9) | 33 (33.8) | <0.001 |
| Number of territories with plaque | 2 [1.0;3.0] | 2 [1.0;3.0] | 0.398 |
| cIMTf (mm) | 0.73 [0.65;0.89] | 0.64 [0.56;0.74] | <0.001 |
| Ankle-Brachial index (%) | |||
| ABI ≤0.9 | 11 (12.5) | 6 (7.14) | 0.357 |
| ABI >0.9-<1.4 | 57 (64.8) | 64 (76.2) | 0.141 |
| ABI ≥ 1.4 | 20 (22.7) | 14 (16.7) | 0.420 |
| Dialysis modality: | 0.437 | ||
| Hemodialysis | 44 (49.4) | 48 (56.5) | |
| Peritoneal dialysis | 45 (50.6) | 37 (43.5) |
Data are presented as median [interquartile range], mean (standard deviation) or n (%).
a Atheromatous vascular disease
b Angiotensin converting enzyme inhibitors
c Angiotensin II receptor blockers
d Erythropoiesis stimulating agents
e Calcium
f Common carotid artery intima media thickness